Full Press Release Details
MediciNova Reports Second Quarter 2010 Results
SAN DIEGO, Calif. August 16, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market
(Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended June 30, 2010.
A detailed discussion of financial results and product development programs can be found in MediciNova s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2010, which was filed August 16, 2010 and is available through investors.medicinova.com.
For the quarter ended June 30, 2010, MediciNova reported a net loss of $4.3 million, or $0.35 per share, compared to a net
loss of $4.7 million, or $0.39 per share, for the same period last year. There were no revenues for the quarter ended June 30, 2010 or June 30, 2009. Research and development expenses were $2.3 million for the quarter ended June 30,
2010, compared to $2.7 million for the quarter ended June 30, 2009. The decrease in research and development expenses was due to a decrease in spending on our prioritized asset MN-221 for the treatment of acute exacerbations of asthma due to
slowed enrollment in the on-going MN-221-CL-007 clinical trial set in the emergency department, offset by increased spending on our ibudilast program as we incurred expenditures related to the completion of a preclinical monkey toxicity study and
the AV411 opioid withdrawal clinical trial. General and administrative expenses were $1.8 million for the quarter ended June 30, 2010, compared to $2.2 million for the quarter ended June 30, 2009. The decrease in general and administrative
expenses was due primarily to a decrease in fees paid for legal and accounting services due to the completion of the Avigen transaction in 2009.
As of June 30, 2010, the carrying value of our cash, cash equivalents, investment securities current and ARS Put, net of the ARS Loan, was
$34.8 million, compared to $28.4 million at December 31, 2009. Restricted cash and letter of credit of $28.8 million will be included in our capital resources upon conversion of the associated convertible notes into our common stock.
At June 30, 2010, $9.9 million of our Auction Rate Securities ( ARS ) consisted primarily of government-guaranteed student
loan securities and were classified as current investment securities. At June 30, 2010, $1.8 million of our ARS consisted of private placement securities and were classified as long-term investment securities. None of the underlying collateral
for our ARS consisted of subprime mortgages or collateralized debt obligations.
Our ARS Loan balance at June 30, 2010 was $2.0 million and we exercised our ARS Put on June 30,
In the second quarter we made significant progress in strengthening our company. We are pleased that Michael Coffee joined our management team as
Chief Business Officer as we actively pursue potential partnership opportunities for both our core compounds: MN-166 and MN-221, said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. In addition, the
clinical development of MN-221 continues to progress and with asthma season up-coming, in conjunction with a protocol amendment, we anticipate enrollment in the on-going clinical trial to accelerate.
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates,
each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova s pipeline includes six clinical-stage
compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary
incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova s current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of
asthma and COPD exacerbations and MN-166 for the treatment of multiple sclerosis and other central nervous system disorders. We intend to establish strategic collaborations to support further development of our prioritized product candidates.
MediciNova will seek to monetize its other product candidates. For more information on MediciNova, Inc., please visit www.medicinova.com.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding MediciNova s clinical trials supporting safety and efficacy of product candidates and the
potential novelty of such product candidates as treatments for disease, plans and objectives for present and future clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity
and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates,
projects, can, could, may, will, would, or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or
events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements, include, but
are not limited to, the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of
clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the
adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities, the timing of expected filings with the FDA, MediciNova s failure to execute strategic
plans or strategies successfully, MediciNova s collaborations with third parties, MediciNova s ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast
development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program, the availability of funds to complete product development plans and
MediciNova s ability to raise sufficient capital when needed, intellectual property or contract rights, and the other risks and uncertainties described in MediciNova s filings with the Securities and Exchange Commission, including its
annual report on Form 10-K for the year ended December 31, 2009 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
CONTACT: MediciNova, Inc.
Shintaro Asako, Chief Financial Officer
CONSOLIDATED BALANCE SHEETS
| June 30, 2010 | December 31, 2009 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,357,050 | $ | 19,241,581 | ||||
| Investment securities-current | 9,902,415 | 24,254,987 | ||||||
| ARS put-current | 1,587,881 | 2,557,007 | ||||||
| Restricted letter of credit | 500,292 | |||||||
| Prepaid expenses and other current assets | 1,147,200 | 869,649 | ||||||
| Total current assets | 38,494,838 | 46,923,224 | ||||||
| Restricted cash | 28,296,766 | 30,045,965 | ||||||
| Restricted investment | 643,098 | 676,499 | ||||||
| Restricted letter of credit | 500,042 | |||||||
| In-process research and development | 4,800,000 | 4,800,000 | ||||||
| Goodwill | 9,368,205 | 9,142,205 | ||||||
| Property and equipment, net | 90,381 | 153,547 | ||||||
| Long-term investments | 1,769,468 | 2,085,425 | ||||||
| Other assets | 167,986 | |||||||
| Total assets | $ | 83,630,742 | $ | 94,326,907 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 514,605 | $ | 1,300,271 | ||||
| ARS loan payable | 2,002,624 | 17,605,485 | ||||||
| Current portion of long-term debt | 2,178,849 | |||||||
| Escrow holdback | 1,094,324 | 1,094,045 | ||||||
| Accrued expenses | 1,184,638 | 1,276,036 | ||||||
| Accrued compensation and related expenses | 289,327 | 1,146,960 | ||||||
| Total current liabilities | 7,264,367 | 22,422,797 | ||||||
| Management transition plan liability | 643,098 | 676,499 | ||||||
| Deferred tax liability | 1,956,000 | 1,956,000 | ||||||
| Convertible notes | 27,571,523 | 29,258,137 | ||||||
| Long-term debt, less current portion | 11,904,359 | |||||||
| Total liabilities | 49,339,347 | 54,313,433 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders equity: | ||||||||
| Preferred stock, $0.01 par value; 500,000 shares authorized at June 30, 2010 and December 31, 2009; no shares outstanding at June 30, 2010 and December 31, 2009 | ||||||||
| Common stock, $0.001 par value; 30,000,000 shares authorized at June 30, 2010 and December 31, 2009; 12,448,520 and 12,172,510 shares issued at June 30, 2010 and December 31, 2009, respectively, and 12,402,713 and 12,122,217 shares outstanding at June 30, 2010 and December 31, 2009, respectively | 12,449 | 12,170 | ||||||
| Additional paid-in capital | 292,401,018 | 288,652,712 | ||||||
| Accumulated other comprehensive loss | (63,375 | ) | (64,914 | ) | ||||
| Treasury stock, at cost; 45,807 shares at June 30, 2010 and 50,293 shares at December 31, 2009 | (1,212,288 | ) | (1,235,395 | ) | ||||
| Deficit accumulated during the development stage | (256,846,409 | ) | (247,351,099 | ) | ||||
| Total stockholders equity | 34,291,395 | 40,013,474 | ||||||
| Total liabilities and stockholders equity | $ | 83,630,742 | $ | 94,326,907 |
CONSOLIDATED STATEMENTS OF OPERATIONS
| Three months ended June 30, | Six months ended June 30, | Period from September 26, 2000 (inception) to June 30, 2010 | ||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||||||
| Revenues | $ | $ | $ | $ | $ | 1,558,227 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Cost of revenues | 1,258,421 | |||||||||||||||||||
| Research and development | 2,304,518 | 2,745,816 | 5,253,974 | 5,846,717 | 149,799,841 | |||||||||||||||
| General and administrative | 1,847,284 | 2,198,883 | 4,134,236 | 4,363,077 | 93,161,234 | |||||||||||||||
| Total operating expenses | 4,151,802 | 4,944,699 | 9,388,210 | 10,209,794 | 244,219,496 | |||||||||||||||
| Operating loss | (4,151,802 | ) | (4,944,699 | ) | (9,388,210 | ) | (10,209,794 | ) | (242,661,269 | ) | ||||||||||
| Gain/(impairment charge) on investment securities | 64,018 | 114,155 | 56,539 | 140,826 | (893,196 | ) | ||||||||||||||
| Foreign exchange gain/(loss) | 2,020 | (17,912 | ) | (1,726 | ) | 9,176 | (103,507 | ) | ||||||||||||
| Other expense | (43,324 | ) | (74,631 | ) | (74,631 | ) | ||||||||||||||
| Interest expense | (406,269 | ) | (65,118 | ) | (450,443 | ) | (107,595 | ) | (692,815 | ) | ||||||||||
| Other income | 201,297 | 248,738 | 362,410 | 509,165 | 18,981,946 | |||||||||||||||
| Income taxes | 751 | (5 | ) | (39,815 | ) | |||||||||||||||
| Net loss | (4,334,060 | ) | (4,664,836 | ) | (9,495,310 | ) | (9,658,227 | ) | (225,483,287 | ) | ||||||||||
| Accretion to redemption value of redeemable convertible preferred stock | (98,445 | ) | ||||||||||||||||||
| Deemed dividend resulting from beneficial conversion feature on Series C redeemable convertible preferred stock | (31,264,677 | ) | ||||||||||||||||||
| Net loss applicable to common stockholders | $ | (4,334,060 | ) | $ | (4,664,836 | ) | $ | (9,495,310 | ) | $ | (9,658,227 | ) | $ | (256,846,409 | ) | |||||
| Basic and diluted net loss per common share | $ | (0.35 | ) | $ | (0.39 | ) | $ | (0.77 | ) | $ | (0.80 | ) | ||||||||
| Shares used to compute basic and diluted net loss per common share | 12,431,395 | 12,072,027 | 12,350,697 | 12,072,027 |